• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Biologics for psoriasis in COVID-19 era: What do we know?

作者信息

Megna Matteo, Napolitano Maddalena, Patruno Cataldo, Fabbrocini Gabriella

机构信息

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.

出版信息

Dermatol Ther. 2020 Jul;33(4):e13467. doi: 10.1111/dth.13467. Epub 2020 Jun 15.

DOI:10.1111/dth.13467
PMID:32338424
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7261982/
Abstract
摘要

相似文献

1
Biologics for psoriasis in COVID-19 era: What do we know?新冠疫情时代用于治疗银屑病的生物制剂：我们了解什么？
Dermatol Ther. 2020 Jul;33(4):e13467. doi: 10.1111/dth.13467. Epub 2020 Jun 15.
2
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears.新冠疫情时代银屑病患者使用生物制剂：证据增多，恐惧减少。
J Dermatolog Treat. 2020 Jun;31(4):328-329. doi: 10.1080/09546634.2020.1757605. Epub 2020 Apr 27.
3
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
4
Antipsoriatic treatments during COVID-19 outbreak.新冠疫情期间的银屑病治疗
Dermatol Ther. 2020 Jul;33(4):e13345. doi: 10.1111/dth.13345. Epub 2020 Apr 10.
5
Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".关于《COVID-19与银屑病：是时候限制免疫抑制剂治疗了吗？行动呼吁》的评论
Dermatol Ther. 2020 Jul;33(4):e13360. doi: 10.1111/dth.13360. Epub 2020 Apr 16.
6
Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.银屑病和银屑病关节炎：在新冠疫情期间如何管理免疫抑制剂
Dermatol Ther. 2020 Jul;33(4):e13415. doi: 10.1111/dth.13415. Epub 2020 May 2.
7
Comment on "Antipsoriatic treatments during COVID-19 outbreak".关于“新冠肺炎疫情期间的银屑病治疗”的评论
Dermatol Ther. 2020 Jul;33(4):e13491. doi: 10.1111/dth.13491. Epub 2020 Jun 12.
8
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素17通路抑制生物制剂治疗的银屑病患者发生呼吸道感染和症状的风险：对COVID-19大流行期间决策相关关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.
9
Reply to: "Biologics for psoriasis during COVID-19 outbreak".回复：“新冠疫情期间用于银屑病的生物制剂”
J Am Acad Dermatol. 2020 Jun;82(6):e219. doi: 10.1016/j.jaad.2020.04.014. Epub 2020 Apr 10.
10
COVID-19 and immunomodulator/immunosuppressant use in dermatology.新型冠状病毒肺炎与皮肤科中免疫调节剂/免疫抑制剂的应用
J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26.

引用本文的文献

1
The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.银屑病、COVID-19 感染与治疗期间疫苗接种的关系。
Adv Exp Med Biol. 2023;1412:339-355. doi: 10.1007/978-3-031-28012-2_18.
2
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.
3
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.银屑病患者接受白细胞介素-17 抑制剂治疗后感染 COVID-19、住院和死亡的风险：系统评价和荟萃分析。
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
4
Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.新冠疫情期间接受生物制剂治疗的银屑病和化脓性汗腺炎患者的皮肤表现
J Clin Med. 2021 Dec 13;10(24):5841. doi: 10.3390/jcm10245841.
5
Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders.4 例风湿免疫病患者应用单克隆抗体治疗轻中度 COVID-19。
Med Sci Monit. 2021 Nov 25;27:e934267. doi: 10.12659/MSM.934267.
6
Literature Overview of the IL-17 Inhibition from Psoriasis to COVID-19.从银屑病到新冠肺炎的白细胞介素-17抑制作用文献综述
J Inflamm Res. 2021 Nov 1;14:5611-5618. doi: 10.2147/JIR.S329252. eCollection 2021.
7
What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?新冠疫情后银屑病关节炎的治疗有哪些变化？
Eurasian J Med. 2021 Jun;53(2):132-136. doi: 10.5152/eurasianjmed.2021.20222.
8
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
9
Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review.平息重症新型冠状病毒肺炎感染中的炎症风暴：生物制剂的作用——一篇叙述性综述
Saudi Pharm J. 2021 Mar;29(3):213-222. doi: 10.1016/j.jsps.2021.01.005. Epub 2021 Feb 2.
10
Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy).2019冠状病毒病大流行期间的银屑病管理：银屑病特别兴趣小组（印度皮肤科、性病与麻风病学协会学会）的建议
Indian Dermatol Online J. 2021 Jan 16;12(1):58-65. doi: 10.4103/idoj.IDOJ_685_20. eCollection 2021 Jan-Feb.

本文引用的文献

1
Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?银屑病缓解后停用肿瘤坏死因子拮抗剂是否可行？
Ann Dermatol. 2019 Oct;31(5):495-501. doi: 10.5021/ad.2019.31.5.495. Epub 2019 Aug 30.
2
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.新型冠状病毒肺炎与银屑病：是时候限制免疫抑制剂的使用了吗？呼吁采取行动。
Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.
3
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
4
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.降低2019新型冠状病毒所致死亡率：宿主导向疗法应成为一种选择。
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
Coronavirus infections and immune responses.冠状病毒感染与免疫应答。
J Med Virol. 2020 Apr;92(4):424-432. doi: 10.1002/jmv.25685. Epub 2020 Feb 7.
7
IL-17 boosts proinflammatory outcome of antiviral response in human cells.IL-17 增强了人类细胞抗病毒反应中的促炎效果。
J Immunol. 2011 Nov 15;187(10):5357-62. doi: 10.4049/jimmunol.1100917. Epub 2011 Sep 30.